While ultra-short therapy remains tempting, eight weeks may represent the practical minimum for reliably eradicating recently ...

Study evaluated the epidemiological and economic effects of implementing preference-driven PrEP among MSM and transgender ...

Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began ...

People living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac ...

A 2024 protocol published in BMJ Open, outlining a planned systematic review to quantify that excess burden worldwide, noted ...

New findings give reason to start thinking about an off-label switch strategy involving a pair of injectables rarely ...

Providers need to consider the risk of new or reactivated HBV before switching a patient to a tenofovir-sparing regimen.

A prominent protein on most human cells may be key to unlocking the code that makes humans susceptible to pathogenic bacteria ...

US study reveals how HIV developed resistance after breakthrough infections in a landmark antibody-prevention trial.

No women taking long-acting cabotegravir (Apretude) for HIV PrEP developed an HIV infection despite short delays before some maintenance injections, according to a US study of routine clinical care.

In the era of universal test-and-treat and new antiretroviral regimens, the data reinforce support for TPT as an essential ...

In September, the Eurasian Community for Access to Treatment (ECAT) sent a letter to Otsuka calling for urgent action to ...